NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 362 filers reported holding NOVOCURE LTD in Q2 2021. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $463,973 | -56.8% | 28,729 | +10.9% | 0.00% | -55.6% |
Q2 2023 | $1,074,933 | -34.9% | 25,902 | -5.7% | 0.01% | -40.0% |
Q1 2023 | $1,651,444 | -15.6% | 27,460 | +2.9% | 0.02% | -21.1% |
Q4 2022 | $1,957,125 | -0.4% | 26,682 | +3.2% | 0.02% | -5.0% |
Q3 2022 | $1,964,000 | +7.7% | 25,844 | -1.5% | 0.02% | +11.1% |
Q2 2022 | $1,823,000 | -15.4% | 26,228 | +0.8% | 0.02% | +5.9% |
Q1 2022 | $2,155,000 | +13.0% | 26,009 | +2.4% | 0.02% | +13.3% |
Q4 2021 | $1,907,000 | -37.1% | 25,398 | -2.8% | 0.02% | -40.0% |
Q3 2021 | $3,034,000 | -47.5% | 26,119 | +0.3% | 0.02% | -46.8% |
Q2 2021 | $5,779,000 | +75.2% | 26,052 | +4.4% | 0.05% | +62.1% |
Q1 2021 | $3,298,000 | -22.7% | 24,948 | +1.2% | 0.03% | -25.6% |
Q4 2020 | $4,264,000 | +48.7% | 24,640 | -4.3% | 0.04% | +34.5% |
Q3 2020 | $2,867,000 | +152.8% | 25,760 | +34.8% | 0.03% | +81.2% |
Q2 2020 | $1,134,000 | -9.4% | 19,116 | +2.8% | 0.02% | -27.3% |
Q1 2020 | $1,252,000 | – | 18,587 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Invus Financial Advisors, LLC | 350,884 | $24,386,000 | 14.72% |
HARTLINE INVESTMENT CORP/ | 335,191 | $58,001,000 | 8.32% |
Deep Track Capital, LP | 1,341,300 | $93,220,000 | 6.13% |
MORGAN JESS S & CO INC | 48,345 | $3,360,000 | 3.48% |
Taylor Frigon Capital Management LLC | 68,908 | $4,789,000 | 2.49% |
HighVista Strategies LLC | 28,007 | $1,946,000 | 1.18% |
Private Harbour Investment Management & Counsel, LLC | 13,106 | $911,000 | 1.01% |
Lloyd Park, LLC | 9,325 | $648,000 | 0.68% |
Baillie Gifford | 9,116,230 | $633,578,000 | 0.65% |
HAP Trading, LLC | 110,900 | $10,575,000 | 0.53% |